Audit: QRS - Clascoterone for Hair Regrowth
Audit conducted on 08/08/2026 11:21 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 91 |
| Passed | 81 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked against ER: protocol regimen (ER 402, 412, 416, 424), time-to-effect (ER 457), benefit/risk headings (ER 184–319), contraindications (ER 362–374), interactions (ER 343–357), monitoring table (ER 489–497), qualitative markers (ER 503–508), at-a-glance (ER 532–536). |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “theoretical risk of feminizing effects on a male fetus” and “unknown consequences of multi-year androgen receptor blockade” carried over verbatim; “Post-marketing signals for…” retains the ER’s signal-not-causation framing. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Population qualifiers (“in men with mild-to-moderate pattern hair loss”, “in younger women”) are retained rather than generalised; contraindications keep their thresholds. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications drawn only from ER “Populations Who Should Avoid This Intervention”; Key Interactions only from ER “Key Interactions & Contraindications” bullets; no Benefit- or Risk-Modifying Factor is surfaced as a gate. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT identifiers, expert names or brand names (Winlevi, Breezula) appear anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No sponsor, investigator or institution is named in the QRS. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Measured, evidence-first framing matches the ER, including the ER’s insistence that the pivotal dataset is unpublished. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Monitoring targets, decision points and qualitative markers give the reader actionable levers without overstating the evidence. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Content is stated descriptively (trial regimen, observed timings, measured ranges) rather than issued as personal instruction. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No “you should”, “consult”, “take” constructions; footer disclaimer is template text. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Protocol cells present the trial regimen; Monitoring presents ranges and cadence. No recommending verbs. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns in any populated span. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms retained only where they are the biomarker or condition name; at-a-glance uses plain-language equivalents (“docking sites”, “male-type hormones”). |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every item is a short phrase or single clause; ER paragraphs are reduced to headline facts. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed across all 61 populated spans. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Functional ranges, baseline-correction step and self-tracking markers assume a proactive, self-directed reader. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Twice-daily indefinite application, baseline lab panel and repeated potassium checks are presented without softening. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | No simplification toward casual use; the unapproved, compounded status and monitoring burden are carried through. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-a-glance foregrounds the unpublished-dataset limitation, which is the decision-relevant signal for this audience. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The string “anti-aging” does not occur in the QRS. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | “solution”, “application site”, “serum potassium”, “thyroid-stimulating hormone” used throughout; no consumer-grade substitutions. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why” |
🟢 | All fixed headings present and unmodified (QRS lines 445, 491, 542, 575, 598, 627, 656, 660–662, 782); tier labels present in both Benefits and Risks. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | 61 named spans present and consistently numbered: page_title, header_, at_a_glance, action_1–3 (label/value/sub), time_1–3 (label/value/sub), benefits_, stop_items, caution_items, risks_*, marker_1–7 (name/target/why), monitoring_cadence, qualitative_item_1–6. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The website="evidence_review", website="audit" and website="full_review" placeholders and the footer disclaimer are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section relevant to the QRS is empty; every tier and every gate has content. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Monitoring row labels reproduce the ER biomarker names verbatim; gate items reproduce the ER bold labels (e.g., “Potassium supplements and potassium-based salt substitutes”, “Antiandrogenic supplements”, “Licorice root”). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No invented biomarker or gate label; acronym expansions from the ER table (“HPA”, “eGFR”, “TSH”) are dropped rather than substituted. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji characters in the file; the ER’s 🟩/🟥/🟨 and ⚠️ markers are not carried over. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed to its per-section budget: ER paragraphs become single clauses, benefit/risk tiers are collapsed to one line each, and the monitoring “Why” column is reduced to the ER’s short rationale. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Comment opens on line 2, immediately after <!doctype html> on line 1, and closes on line 14 before the template comment. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- on line 3, closing --- on line 13; the descriptive text on line 2 precedes the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is echoed into the body except the template-mandated creation date and model name. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, correctly, because the value contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: clascoterone_hair_2026-0808-0711_Opus_ER.md, matching the ER’s own filename frontmatter. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0808-1109, correct format. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version only, no context-window or tier qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: clascoterone_hair_2026-0808-0711_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All nine keys carry trimmed, unquoted values except the colon-bearing duration. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Clascoterone for Hair Regrowth - Quick Reference Sheet”; ER canonical_topic is “Clascoterone for Hair Regrowth”; no entity encoding required. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Clascoterone for Hair Regrowth”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “08/08/2026” from qrs_creation_date: 2026-0808-1109. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”, matching qrs_creator_ai_fullname. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header carries only the title and the template subline; the ER’s “Also known as” line (Cortexolone 17α-propionate, CB-03-01, Breezula, Winlevi) is not reproduced. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Compresses the ER Conclusion (lines 532–536) into mechanism, what the scalp trials showed, the publication gap, and regulatory status. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 56 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Mechanism and inactivation → ER 532; gains built over a year and faded on stopping → ER 534; never published in full → ER 534; no regulator approval → ER 400 and 446. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | Uses “skin-applied hormone blocker”, “docking sites”, “male-type hormones”, “inactive form” instead of topical antiandrogen, androgen receptor, dihydrotestosterone, cortexolone. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | “Late-stage trials in men” only; SCALP 1/SCALP 2, 1,465 participants and p-values are all omitted. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No percentages, risk ratios or confidence intervals; the ER’s 539%/168%/239% figures are not carried over. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All seven items map to the “Populations Who Should Avoid This Intervention” subsection (ER lines 362–374). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All seven ER contraindications are present, none added: pregnancy/breastfeeding, childbearing potential without contraception, adrenal insufficiency/systemic corticosteroids, CKD 3b or K⁺ >5.0, active scalp disease, non-androgenetic hair loss, under-18s. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Seven discrete <li> elements inside the stop_items span (QRS lines 578–593). |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s post-em-dash explanations (e.g., “Any condition already compromising the cortisol axis — Addison’s disease…”, “…delays correct diagnosis…”) are all stripped; no dash-led clause survives. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “stage 3b or worse”, “below 45 mL/min/1.73 m²”, “above 5.0 mEq/L”, “under 18” retained; disease examples kept in parentheses while the ER’s explanatory glosses are dropped. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in its contraindication bullets. |
| 8.7 | If no [stop_items] are present the section is left empty | N/A | Seven contraindications are present. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All nine items map to ER lines 343–357. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | The ER’s “Systemic corticosteroids” bullet is correctly omitted because “current systemic corticosteroid therapy” is already a contraindication; the remaining seven ER bullets are represented (the composite “Over-the-counter medications” and “Other hair-loss interventions” bullets are split into their distinct agents). |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Nine discrete <li> elements inside the caution_items span (QRS lines 601–617). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s “— caution, monitor” tags and all mechanism/mitigation prose are stripped; no item carries a trailing clause. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Drug-class examples (ACE inhibitors, ARBs, potassium-sparing diuretics, direct renin inhibitors), NSAID examples, the antiandrogenic-supplement list, and the “within 24 hours of application” microneedling window are all retained. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in its interaction bullets. |
| 9.7 | If no [caution_items] are present the section is left empty | N/A | Nine key interactions are present. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Dose and technique from ER 402 and 461; frequency and split dosing from ER 402, 412 and 416; baseline biomarkers from ER 424. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose (1.5 mL of 5% solution), Frequency (twice daily, continuously) and Baseline biomarkers are the three implementation decisions the ER Protocol section turns on. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies well over three actionable aspects; all three sets are populated. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine action spans carry substantive, ER-derived content; none is a placeholder. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | 6 months (co-primary endpoints / earliest decision point), 12 months (continued accrual / fairer assessment) and 3 months (first measurable change) — the three horizons the ER names at line 457. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered by the ER’s own benefit ranking: scalp hair count first, continued accrual second, first measurable change last as the earliest but least conclusive signal. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three distinct time-to-effect horizons; all three sets are populated. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine time spans carry ER-derived labels, values and sub-lines. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides explicit time-to-effect data (line 457), so the section is retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All nine benefit statements correspond one-to-one with the ER’s Expected Benefits sub-headings (ER lines 184–241). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated at the correct tiers (QRS lines 544–568). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the ER sub-heading reduced to its key fact; the ER’s Magnitude lines (risk ratio 2.87, 539%/168%, 239%, 24.5%) are all dropped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any benefits item. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER benefit tiers contain items, so no span needs hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All eight risk statements correspond one-to-one with the ER’s Potential Risks & Side Effects sub-headings (ER lines 270–319). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated at the correct tiers (QRS lines 629–650). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | The ER’s Magnitude lines (7–12% erythema/pruritus, 3 of 42 subjects, 5% vs 4% potassium shifts, reporting odds ratios 1.83 and 1.88) are all dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any risks item. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER risk tiers contain items, so no span needs hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Markers, targets and rationales reproduce the ER Monitoring Protocol & Defining Success table (ER lines 487–495). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All seven ER biomarkers present with matching targets: serum potassium 4.0–4.5 mEq/L, morning cortisol 12–18 µg/dL, ferritin 70–100 ng/mL, TSH 0.5–2.0 mIU/L, 25-hydroxyvitamin D 40–60 ng/mL, comprehensive metabolic panel with eGFR above 60, total testosterone 500–900 ng/dL. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | QRS lines 770–776 reproduce the ER’s cadence at line 497: 4 weeks, 3 months, 6 months, then every 6–12 months, plus a check after starting a potassium-raising medication. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All six items map to the ER’s “Qualitative markers to track alongside the numbers” list (ER lines 503–508). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six present: daily shedding volume, scalp comfort, hair texture and styling behaviour, density at the part line and temples, energy/alertness/postural symptoms, confidence and appearance-related mood. |
Issues 08/08/2026 11:21
Pass rate 100.00%. No issues found.
Issues 08/08/2026 11:12
- 9.2 — Corticosteroids duplicated across gates: “Systemic corticosteroids (oral, injected, high-potency inhaled)” appears as a Key Interaction at QRS line 605 even though “current systemic corticosteroid therapy” is already a Contraindication at line 580, so the same agent class occupies both the stop gate and the caution gate.
Fixes 08/08/2026 11:12
- 9.2 — Corticosteroids duplicated across gates: Removed the “Systemic corticosteroids (oral, injected, high-potency inhaled)” item from
caution_items, since “current systemic corticosteroid therapy” is already carried instop_itemsas a contraindication.